Search results
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Published: 05 March 2021. Authors: ESMO Guidelines Committee. Note: This eUpdate replaces all previous eUpdates published for these guidelines.
29 sty 2024 · Learn about the treatment options for hepatocellular carcinoma (HCC), a type of liver cancer, based on disease stage, location, and characteristics. Find out the recommended regimens for surgery, transplantation, locoregional therapies, and systemic therapies.
Timeline of major phase 3 clinical trials of first-line treatments for advanced hepatocellular carcinoma by year of publication or presentation at a national meeting. HAIC, hepatic arterial infusion chemotherapy; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; TTP, time to progression.
5 mar 2021 · Atezolizumab plus bevacizumab is the first treatment to demonstrate a significant OS benefit compared with sorafenib with a hazard ratio for death of 0.66 [95% confidence interval (CI) 0.52-0.85; P = 0.0009] in data reported from a recent abstract. 2 Consequently, atezolizumab plus bevacizumab will become the standard of care in first-line syste...
4 sty 2024 · Abstract. Practical Applications. Introduction. Advanced HCC. Locally Advanced. Curative Setting. Child-Pugh Score and Systemic Treatment. Further Considerations: HCC Etiology, the Microenvironment, and Emerging Biomarkers. Acknowledgment. Authors’ Disclosures of Potential Conflicts of Interest and Data Availability Statement. References.
What are the recommended treatment options for first-line and subsequent systemic therapy for patients with advanced hepatocellular carcinoma (ie, patients who are unresectable and not amenable to local therapies)?
25 kwi 2024 · In the ASCO Guideline, Atezolizumab + Bevacizumab or Durvalumab + Tremelimumab Are Recommended as First-line Treatment Options for Patients with Child-pugh Class A and Eastern Cooperative Oncology Group Performance Status 0-1 Advanced HCC.
